# reload+after+2024-01-22 19:43:06.375685
address1§701 Veterans Circle
city§Warminster
state§PA
zip§18974
country§United States
phone§267 469 0914
fax§267 282 0411
website§https://www.arbutusbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
fullTimeEmployees§96
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael J. McElhaugh', 'age': 48, 'title': 'Co-Founder, COO, Chief Business Officer, Director, Interim President & CEO', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 606625, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael J. Sofia Ph.D.', 'age': 65, 'title': 'Chief Scientific Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 628435, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David C. Hastings CPA', 'age': 62, 'title': 'CFO & Chief Accounting Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 647100, 'exercisedValue': 0, 'unexercisedValue': 24750}, {'maxAge': 1, 'name': 'Ms. Lisa M. Caperelli', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. J. Christopher Naftzger BA, Esq., J.D.', 'age': 56, 'title': 'General Counsel & Chief Compliance Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karen  Sims M.D., Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.', 'age': 72, 'title': 'Secretary', 'yearBorn': 1951, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§6
compensationRisk§6
shareHolderRightsRisk§9
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.958
priceToSalesTrailing12Months§18.77436
currency§USD
dateShortInterest§1702598400
forwardEps§-0.44
exchange§NMS
quoteType§EQUITY
shortName§Arbutus Biopharma Corporation
longName§Arbutus Biopharma Corporation
firstTradeDateEpochUtc§1185456600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§327b69f1-b9aa-3465-8efa-89ecddd8ae31
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§4.0
targetMeanPrice§4.6
targetMedianPrice§4.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§6.108
grossMargins§-2.55582
ebitdaMargins§0.0
trailingPegRatio§None
